Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.

Administration, Intranasal Animals Antibodies, Neutralizing / blood Antibodies, Viral / blood CD8-Positive T-Lymphocytes / immunology COVID-19 / prevention & control COVID-19 Vaccines / immunology Cell Line Chlorocebus aethiops Cricetinae Genetic Vectors Immunization, Secondary Immunoglobulin A / blood Immunoglobulin G / blood Lung / immunology Male Mice Mice, Inbred C57BL SARS-CoV-2 / immunology Spike Glycoprotein, Coronavirus / immunology Th1 Cells / immunology Vaccination Vaccines, Subunit / immunology Vaccinia virus / immunology Vero Cells Viral Load / immunology

bronchus-associated lymphoid tissue (BALT) lungs modified vaccinia virus Ankara (MVA) respiratory tract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein vaccination vaccine

Journal

Frontiers in immunology

ISSN: 1664-3224

Titre abrégé: Front Immunol

Pays: Switzerland

ID NLM: 101560960

Informations de publication

Date de publication:
2021

Historique:

received: 07 09 2021

accepted: 25 10 2021

entrez: 3 12 2021

pubmed: 4 12 2021

medline: 15 12 2021

Statut: epublish

Résumé

Antigen-specific tissue-resident memory T cells (Trms) and neutralizing IgA antibodies provide the most effective protection of the lungs from viral infections. To induce those essential components of lung immunity against SARS-CoV-2, we tested various immunization protocols involving intranasal delivery of a novel Modified Vaccinia virus Ankara (MVA)-SARS-2-spike vaccine candidate. We show that a single intranasal MVA-SARS-CoV-2-S application in mice strongly induced pulmonary spike-specific CD8

Identifiants

DOI: 10.3389/fimmu.2021.772240 PMID: 34858430 PMC: PMC8632543

pubmed: 34858430

doi: 10.3389/fimmu.2021.772240

pmc: PMC8632543

doi:

Substances chimiques

Antibodies, Neutralizing 0

Antibodies, Viral 0

COVID-19 Vaccines 0

Immunoglobulin A 0

Immunoglobulin G 0

Spike Glycoprotein, Coronavirus 0

Vaccines, Subunit 0

spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

772240

Informations de copyright

Copyright © 2021 Bošnjak, Odak, Barros-Martins, Sandrock, Hammerschmidt, Permanyer, Patzer, Greorgiev, Gutierrez Jauregui, Tscherne, Schwarz, Kalodimou, Ssebyatika, Ciurkiewicz, Willenzon, Bubke, Ristenpart, Ritter, Tuchel, Meyer zu Natrup, Shin, Clever, Limpinsel, Baumgärtner, Krey, Volz, Sutter and Förster.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

N Engl J Med. 2021 Aug 19;385(8):759-760

pubmed: 34161702

Nat Commun. 2020 Aug 21;11(1):4207

pubmed: 32826924

J Exp Med. 2016 Dec 12;213(13):3057-3073

pubmed: 27815325

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51

pubmed: 1438287

Clin Infect Dis. 2020 Dec 3;71(9):2428-2446

pubmed: 32215622

J Exp Med. 2014 Apr 7;211(4):643-51

pubmed: 24663215

Immunity. 2014 Dec 18;41(6):886-97

pubmed: 25526304

Cell. 2021 Aug 5;184(16):4220-4236.e13

pubmed: 34242578

Cell. 2017 Oct 5;171(2):398-413.e21

pubmed: 28942919

Vaccine. 1998 Aug;16(13):1324-30

pubmed: 9682397

Nature. 2020 Aug;584(7821):437-442

pubmed: 32555388

Virology. 1997 Nov 24;238(2):198-211

pubmed: 9400593

Science. 2020 Mar 13;367(6483):1260-1263

pubmed: 32075877

J Leukoc Biol. 2014 Feb;95(2):215-24

pubmed: 24006506

Viruses. 2017 May 05;9(5):

pubmed: 28475122

Viral Immunol. 2017 Jan/Feb;30(1):70-76

pubmed: 27809679

Lancet. 2021 Jan 9;397(10269):99-111

pubmed: 33306989

N Engl J Med. 2021 Jul 8;385(2):187-189

pubmed: 33951357

Proc Natl Acad Sci U S A. 2021 Jul 13;118(28):

pubmed: 34162739

Lancet Infect Dis. 2014 Oct;14(10):939-46

pubmed: 25151225

J Virol. 2013 Nov;87(21):11950-4

pubmed: 23986586

Cell. 2021 Apr 29;184(9):2384-2393.e12

pubmed: 33794143

Sci Immunol. 2020 Jun 11;5(48):

pubmed: 32527802

Methods Mol Biol. 2016;1350:349-58

pubmed: 26820867

J Gen Virol. 1998 Feb;79 ( Pt 2):347-52

pubmed: 9472619

J Exp Med. 2019 Dec 2;216(12):2736-2747

pubmed: 31558614

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2046-51

pubmed: 18270165

Nature. 2004 Mar 11;428(6979):182-5

pubmed: 15014500

PLoS Pathog. 2022 Sep 30;18(9):e1010876

pubmed: 36178969

Sci Rep. 2018 Jan 16;8(1):864

pubmed: 29339750

Vaccines (Basel). 2020 Oct 03;8(4):

pubmed: 33022950

Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7

pubmed: 34826623

J Exp Med. 2009 Nov 23;206(12):2593-601

pubmed: 19917776

Methods Mol Biol. 2017;1559:185-198

pubmed: 28063045

PLoS Med. 2019 Apr 30;16(4):e1002790

pubmed: 31039172

Nat Biotechnol. 2020 Sep;38(9):1073-1078

pubmed: 32704169

Cell Rep. 2018 Apr 17;23(3):783-795

pubmed: 29669284

J Immunol. 2003 Aug 1;171(3):1602-9

pubmed: 12874255

Cell Mol Immunol. 2021 Apr;18(4):936-944

pubmed: 33139905

Nature. 2020 Jul;583(7818):834-838

pubmed: 32408338

J Virol. 2015 Aug;89(16):8651-6

pubmed: 26018172

N Engl J Med. 2021 May 13;384(19):1866-1868

pubmed: 33761203

Nat Med. 2021 May;27(5):917-924

pubmed: 33772244

Sci Adv. 2021 Jul 2;7(27):

pubmed: 34215591

Immunity. 2021 Mar 9;54(3):542-556.e9

pubmed: 33631118

Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595

pubmed: 32571934

N Engl J Med. 2021 Feb 4;384(5):403-416

pubmed: 33378609

Front Immunol. 2019 Mar 29;10:611

pubmed: 30984186

Vaccine. 1994 Aug;12(11):1032-40

pubmed: 7975844

Lancet Infect Dis. 2020 Jul;20(7):827-838

pubmed: 32325037

N Engl J Med. 2004 Feb 26;350(9):896-903

pubmed: 14985487

Emerg Microbes Infect. 2021 Dec;10(1):797-809

pubmed: 33825619

Cell Host Microbe. 2021 Feb 10;29(2):236-249.e6

pubmed: 33357418

Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343

pubmed: 30357391

Cell. 2020 Oct 1;183(1):169-184.e13

pubmed: 32931734

Expert Rev Vaccines. 2009 Apr;8(4):447-54

pubmed: 19348560

J Immunol. 2019 Jan 15;202(2):374-381

pubmed: 30617119

Sci Immunol. 2017 Jan 6;2(7):

pubmed: 28783666

Hum Vaccin Immunother. 2016 Apr 2;12(4):1070-9

pubmed: 26752023

Nat Immunol. 2011 Dec 16;13(1):1; author reply 2

pubmed: 22179267

Adv Virus Res. 2017;97:187-243

pubmed: 28057259

Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6

pubmed: 15096611

Nat Med. 2021 May;27(5):790-792

pubmed: 33782619

Nat Immunol. 2018 Feb;19(2):173-182

pubmed: 29311694

Emerg Infect Dis. 2020 Jul;26(7):1478-1488

pubmed: 32267220

Immunology. 1989 Jan;66(1):32-8

pubmed: 15493259

Nat Commun. 2020 Nov 30;11(1):6121

pubmed: 33257686

Front Immunol. 2020 Aug 07;11:1959

pubmed: 32849655

Cell Mol Immunol. 2020 Feb;17(2):113-122

pubmed: 31969685

Lancet Infect Dis. 2021 Dec;21(12):1654-1664

pubmed: 34324836

Cell Mol Immunol. 2018 Oct;15(10):875-887

pubmed: 29429996

Vaccine. 2011 Feb 11;29(8):1666-76

pubmed: 21195803

Front Immunol. 2021 Apr 12;12:640842

pubmed: 33912167

PLoS One. 2009 Sep 23;4(9):e7142

pubmed: 19774076

Science. 2016 Jan 1;351(6268):77-81

pubmed: 26678878

Curr Opin Immunol. 2019 Aug;59:101-108

pubmed: 31265968

Lancet. 2021 Apr 10;397(10282):1351-1362

pubmed: 33798499

Front Immunol. 2013 Jul 12;4:185

pubmed: 23874333

Pharmaceutics. 2021 Jul 14;13(7):

pubmed: 34371768

Clin Vaccine Immunol. 2013 May;20(5):663-72

pubmed: 23446219

N Engl J Med. 2021 May 20;384(20):1885-1898

pubmed: 33725432

N Engl J Med. 2020 Dec 31;383(27):2603-2615

pubmed: 33301246

Nat Med. 2021 Sep;27(9):1525-1529

pubmed: 34262158

Vaccine. 2013 Sep 6;31(39):4241-6

pubmed: 23523410

Vaccine. 1999 Oct 14;18(5-6):392-7

pubmed: 10519927